TORONTO, March 21, 2017 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2017 annual general and special meeting of shareholders held on March 21, 2017.
All directors nominated, as listed in the Company's management information circular dated February 15, 2017 (the "Information Circular"), were re-elected as members of the board as follows:
| Director |
Votes For(*) |
% For |
Withheld Votes(*) |
% |
| Michael Cloutier |
55,014,419 |
99.70% |
165,368 |
0.30% |
| Robert S. Pollock |
55,006,380 |
99.69% |
173,407 |
0.31% |
| Timothy G. Sorensen |
54,994,235 |
99.66% |
185,552 |
0.34% |
| David D. Guebert |
55,018,949 |
99.71% |
160,838 |
0.29% |
| Theresa Firestone |
55,018,300 |
99.71% |
161,487 |
0.29% |
| Barry Fishman |
55,014,516 |
99.70% |
165,271 |
0.30% |
| Robert Bloch |
55,001,680 |
99.68% |
178,107 |
0.32% |
(*) Reflects votes represented by proxy
In addition, shareholders of the Company approved:
- the appointment of MNP LLP, Chartered Accountants, as the auditor of Merus to hold office until the next annual meeting of shareholders,
- the amendments to the Company's stock option plan announced on March 13, 2017,
- the continuation of the Company's stock option plan for an additional three year term, and
- the amendments to the Company's articles, as described in the Information Circular, by special resolution.
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.
SOURCE Merus Labs Inc.
Phone: (905) 726-0995, Email: [email protected], Website: www.meruslabs.com
Share this article